Tag: pharmaceutical industry
-

J&J Agrees to Buy Ollin Biosciences for $2.2 Billion Upfront, Adding OLN324
Johnson & Johnson agreed to acquire Ollin Biosciences for $2.2 billion upfront. The deal would add OLN324, a Phase 3 candidate for wet AMD and diabetic macular edema. Early results against Vabysmo highlight differences in retinal imaging and leave open whether OLN324 can preserve vision with fewer injections.
-

FDA Approves Gazyva as First Treatment for Primary Membranous Nephropathy
The FDA approved Gazyva (obinutuzumab) to induce remission of proteinuria in adults with primary membranous nephropathy at risk of disease progression. In the Phase 3 MAJESTY trial, 36% of patients assigned to Gazyva achieved complete remission of proteinuria at week 104, compared with 6% assigned to tacrolimus, according to the FDA.
-

Bayer’s Sunharbo Wins FDA Approval for Secondary Stroke Prevention
Bayer’s Sunharbo (asundexian) is the first FDA-approved Factor XIa inhibitor. Its approval adds an oral treatment option alongside antiplatelet therapy for certain adults after a non-cardioembolic ischemic stroke or high-risk TIA. This article examines the clinical evidence, bleeding considerations and significance of the new drug class.
-

J&J’s Rybrevant Faspro Gains FDA Accelerated Approval for Head and Neck Cancer
Rybrevant Faspro expands beyond lung cancer with FDA accelerated approval for certain adults with previously treated recurrent or metastatic head and neck squamous cell carcinoma. Here’s who qualifies and what the OrigAMI-4 study showed.
-

Genmab’s Petosemtamab–Keytruda Combination Improves Survival in Phase 3 Head and Neck Cancer Trial
Genmab’s petosemtamab plus Keytruda improved survival in Phase 3 head and neck cancer testing. A closer look at the findings and their meaning for patients.
-

Astellas Secures Option on Audax’s IL-12 Cancer Therapy DAX-044
Astellas secured an option to license Audax’s DAX-044, a preclinical IL-12 immunotherapy designed to focus immune activation within the tumor microenvironment.
-

Roche’s Divarasib Improves Survival in Phase 3 KRAS G12C Lung Cancer Trial
Roche’s divarasib improved median overall survival to 17.7 months versus 12.0 months with sotorasib or adagrasib in Phase 3 Krascendo 1. The findings inform treatment choice in KRAS G12C-mutated lung cancer but do not establish efficacy after KRAS-inhibitor resistance.
-

AstraZeneca’s Ultomiris Wins FDA Accelerated Approval for IgA Nephropathy
AstraZeneca’s Ultomiris won FDA accelerated approval to reduce proteinuria in adults with primary IgA nephropathy. Phase 3 results support C5 inhibition, while long-term kidney-function benefit remains unconfirmed.
-

GSK’s Hibsago Wins FDA Approval for Chronic Hepatitis B
GSK’s Hibsago (bepirovirsen) won FDA approval for selected adults with chronic hepatitis B. Explore its 19% functional cure result, RNA-targeting mechanism, treatment requirements and key safety risks.
